MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
Keiretsu Forum
Industry: Silicon Valley, California
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM)*
Organization & Developments: Mirum
Parents
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM)*
Children
*Mirum's scientific forte is in developing innovative investigative drug candidates for adult and pediatric orphan cholestatic liver diseases.
2019: Mirum Pharmaceuticals On Maralixibat And Volixibat In Adult PBC: Itching To Know_seekingalpha.com
2020: Mirum: Upcoming Catalyst In Rare Liver Disease, Strong Pipeline And DataMirum: Upcoming Catalyst In Rare Liver Disease, Strong Pipeline And Data
2021: Mirum: Rare Disease Play With Upcoming Catalysts
2022: Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent_seekingalpha.com
2022: Mirum: Potential For European Approval To Move It Forward_ seekingalpha.com
2023: Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss_seekingalpha.com
2023: Mirum Pharmaceuticals: Staying The Course_ seekingalpha.com
2024: Mirum Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Mirum Pharmaceuticals: Advancing On Several Key Fronts
2024: Mirum Pharmaceuticals: Buy At Dips For Volixibat Potential
2024: Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
2024: Mirum Pharmaceuticals' SWOT analysis: liver disease specialist's stock poised for growth
2024: Mirum scores 2nd FDA nod for rare liver disease drug Livmarli, this one to treat PFIC
2024: US FDA approves expanded use of Mirum's liver disease drug
2025: Rare Metabolic Disease’s First FDA-Approved Drug
Jumps
*Key People: Mirum
Finance & Acquisitions: Mirum